A Study of LY3022855 In Participants With Breast or Prostate Cancer

Phase 1 Completed 34 enrolled Eli Lilly and Company

Non-randomizedSingle-groupOpen-labelBasic science

Summary

The main purpose of this study is to learn more about how the investigational drug, LY3022855, affects the immune system in participants with advanced breast or prostate cancer that has not responded to other treatments. Treatment may last up to 6 cycles (cycle = 6 weeks).

Timeline

Start: 2015-05-01
Primary completion: 2017-11-03
Completion: 2017-11-03

Publications

Autio KA, Klebanoff CA, Schaer D, Kauh JSW, Slovin SF, Adamow M, Blinder VS, Brahmachary M, Carlsen M, Comen E, Danila DC, Doman TN, Durack JC, Fox JJ, Gluskin JS, Hoffman DM, Kang S, Kang P, Landa J, McAndrew PF, Modi S, Morris MJ, Novosiadly R, Rathkopf DE, Sanford R, Chapman SC, Tate CM, Yu D, Wong P, McArthur HL. Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study. Clin Cancer Res. 2020 Nov 1;26(21):5609-5620. doi: 10.1158/1078-0432.CCR-20-0855. Epub 2020 Aug 26.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LY3022855	Monoclonal antibody	1 mg/kg	Intravenous
Subject	LY3022855	Monoclonal antibody	1.25 mg/kg	Intravenous
Subject	LY3022855	Monoclonal antibody	100 mg	Intravenous

A Study of LY3022855 In Participants With Breast or Prostate Cancer

Summary

Timeline

Publications

Drugs

Indications